---
document_datetime: 2023-09-21 22:19:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/miglustat-dipharma-epar-all-authorised-presentations_en.pdf
document_name: miglustat-dipharma-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.5078572
conversion_datetime: 2025-12-18 22:57:25.514282
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## EMA procedure number (Invented) name Strength Pharmaceutical form Route of administration Immediate Packaging Pack size

EU/1/18/1346/001

EU/1/18/1346/002

EU/1/18/1346/003

Miglustat Dipharma

Miglustat Dipharma

Miglustat Dipharma

100 mg

100 mg

100 mg

Capsule, hard

Capsule, hard

Capsule, hard

Oral use

Oral use

Oral use blister

(PCTFE/PVC/Alu)

blister

(PCTFE/PVC/Alu)

blister

(PCTFE/PVC/Alu) in wallet card

84 capsules

84 x 1 capsules

(unit dose)

84 capsules